Open Access
VIEWPOINT
Mesenchymal stem cells derived secretome as an innovative cell-free therapeutic approach
1 Department of Basic Medical Sciences, Faculty of Medicine, Yarmouk University, Irbid, 21163, Jordan
2 Physiology and Pathophysiology, Faculty of Medicine, University of Manitoba, Winnipeg, R3E0W2, Canada
3 Department of Pharmacology & Therapeutics, University of Manitoba, Winnipeg, R3E0W2, Canada
4 DREAM, Children’s Hospital Research Institute of Manitoba, Winnipeg, R3E0W2, Canada
* Corresponding Author: EJLAL ABU-EL-RUB. Email:
BIOCELL 2022, 46(4), 907-911. https://doi.org/10.32604/biocell.2022.018306
Received 15 July 2021; Accepted 29 August 2021; Issue published 15 December 2021
Abstract
The paracrine and immunomodulatory cytokines secreted by mesenchymal stem cells (MSCs), generally referred to as the MSCs derived secretome, has substantial potential for the treatment of many chronic and degenerative diseases. MSCs secretome contains both common and disease specific cytokines and modulators that can be beneficial against a wide range of chronic diseases. Herein, we discuss the MSCs secretome composition profile and its translational applicability and the challenges surrounding its use in clinical settings.Keywords
Cite This Article
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.